ICIs for Advanced Pancreatic NETs With High TMB and MMR Alterations
By Jonathan Strosberg, MD - Last Updated: January 29, 2025At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Jonathan Strosberg, MD, of Moffitt Cancer Center, discusses the use of immune checkpoint inhibitors in patients with advanced pancreatic NETs who display high TMB and MMR alterations after treatment with alkylating agents.
Advertisement
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response, and the differences in outcomes between patients with high TMB and MMR alterations.
Advertisement
Related Posts
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.